Empagliflozin belongs to the class sodium-glucose cotransporter-2 inhibitors that improve the outcomes related to heart failure (HF). The underlying mechanisms are not well established, but diuretic properties of empagliflozin are speculated to positively affect outcomes. Compared to traditional diuretics, empagliflozin causes significant natriuresis by acting on the proximal tubule, improving blood volume. This favorable action can offer a substantial advantage in the management of volume status in patients with HF. 1 In recent years, a robust amount of evidence has been generated with Empagliflozin in management of HF through various large clinical trials, in a diverse group of patients.
In this regard, Boehringer Ingelheim India and Docplexus have organized a webinar with the renowned experts, Dr. Faiez Zannad and Dr. C. N. Manjunath , to discuss the clinical development of…
